Cited by 534Protein Degradation and InhibitorsChemical Synthesis and AnalysisUbiquitin and proteasome pathways

The DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index.

Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Churcher, Ian·2018·Journal of Medicinal Chemistry

Open this paper in CoChat — free account

Abstract

Targeted protein degradation, using bifunctional small molecules (Protacs) to remove specific proteins from within cells, has emerged as a novel drug discovery strategy with the potential to offer therapeutic interventions not achievable with existing approaches. In this Perspective, the brief history of the field is surveyed from a drug discovery perspective with a focus on the key advances in knowledge which have led to the definition and exemplification of protein degradation concepts and their resulting applications to medicine discovery. The approach has the potential to bring disruptive change to drug discovery; the many potential advantages and outstanding challenges which lie ahead of this technology are discussed.

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.7b01272

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,484
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Breaking the chains: structure and function of the deubiquitinases
Komander, D., Clague, M. J., & Urbé, S. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2731 · Cited by 1,969
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
THE UBIQUITIN SYSTEM FOR PROTEIN DEGRADATION
Hershko, A., & Ciechanover, A. J. (1992) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.61.070192.003553 · Cited by 1,448
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Self-citation

Show all 67 references

Sorted by citations

Items 201–300 of 534

Experimental Free Ligand Conformations: A Missing Link in Structure-Based Drug Discovery
Chiarparin, E., Packer, M. J., & Wilson, D. M. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0339 · Cited by 34
High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics
Simard, J. R., Lee, L., Vieux, E. F., Improgo, R., Tieu, T. N., Phillips, A. J., Fisher, S. L., Pollock, R. M., & Park, E. Y. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220985049 · Cited by 33
Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification
Osaka, N., Hirota, Y., Ito, D., Ikeda, Y., Kamata, R., Fujii, Y., Chirasani, V. R., Campbell, S. L., Takeuchi, K., Senda, T., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.707439 · Cited by 35
“These proteolysis-targeting chimera (PROTAC) approaches have proven to be an effective strategy for inhibiting specific protein Frontiers in Molecular Biosciences | www.frontiersin.org July 2021 | Volume 8 | Article 7074398 targets (Churcher, 2017; Coleman and Crews, 2018).”
Method
Targeting Protein Kinase, Membrane-Associated Tyrosine/Threonine 1 (PKMYT1) for Precision Cancer Therapy: From Discovery to Clinical Trial
Yang, M., Xiang, H., & Luo, G. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01619 · Cited by 33
Recent Advances on Small-Molecule Bromodomain-Containing Histone Acetyltransferase Inhibitors
Liu, M., Zhang, K., Li, Q., Pang, H., Pan, Z., Huang, X., Wang, L., Wu, F., & He, G. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01638 · Cited by 33
Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency
Chaudhry, C. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02076 · Cited by 35
Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides
Shiah, J. V., Grandis, J. R., & Johnson, D. E. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0599 · Cited by 32
“In addition to properly situating the POI and E3 ubiquitin ligase for the formation of a ternary complex, it also affects physicochemical properties including propensity for cellular uptake, stability, and aqueous solubility (38).”
BackgroundInfluential
Small-molecule PROTACs: Novel Agents for Cancer Therapy
Wan, Y., Yan, C., Gao, H. J., & Liu, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0340 · Cited by 32
Strategies towards potent trypanocidal drugs: Application of Rh-catalyzed [2 + 2 + 2] cycloadditions, sulfonyl phthalide annulation and nitroalkene reactions for the synthesis of substituted quinones and their evaluation against Trypanosoma cruzi
Wood, J. M., Satam, N., Almeida, R. G., Cristani, V. S., de Lima, D. P., Dantas-Pereira, L., Salomão, K., Menna‐Barreto, R. F. S., Namboothiri, I. N. N., Bower, J. F., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115565 · Cited by 31
PROTACs technology for targeting non-oncoproteins: Advances and perspectives
Wang, C., Zhang, Y., Xing, D., & Zhang, R. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105109 · Cited by 32
Construction of an IMiD-based azide library as a kit for PROTAC research
Liu, H., Sun, R., Ren, C., Qiu, X., Yang, X., & Jiang, B. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob02120b · Cited by 30
Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL
Fu, L., Zhang, J., Shen, B., Kong, L., Liu, Y., Tu, W., Wang, W., Cai, X., Wang, X., Cheng, N., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00103 · Cited by 29
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
“sufficient to produce desired pharmacological effect (Burslem & Crews, 2020; Churcher, 2018; Donovan et al., 2020).”
Background
The design, synthesis and anti-tumor mechanism study of new androgen receptor degrader
Xie, H., Liang, J.-J., Wang, Y., Hu, T., Wang, J., Yang, R., Yan, J.-K., Zhang, Q., Xu, X., Liu, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112512 · Cited by 29
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Riching, K. M., Mahan, S. D., Urh, M., & Daniels, D. L. (2020) · Journal of Visualized Experiments · doi:10.3791/61787 · Cited by 30
Structure‐Based Design of a Macrocyclic PROTAC
Testa, A., Hughes, S. J., Lucas, X., Wright, J. E., & Ciulli, A. (2019) · Angewandte Chemie · doi:10.1002/ange.201914396 · Cited by 34
Discovery of NAFLD-Improving Agents by Promoting the Degradation of Keap1
Mingming, Q., Zhong, H., Cheng, Z., Chen, S., Han, X., Shang, J., Chen, L., & Sun, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00822 · Cited by 29
Natural product-based PROteolysis TArgeting Chimeras (PROTACs)
Liu, M., Martyn, A. P., & Quinn, R. J. (2022) · Natural Product Reports · doi:10.1039/d2np00038e · Cited by 29
Small-molecule inhibitors targeting apoptosis signal-regulated kinase 1
Wang, T., Pang, L., He, M., & Wang, Z. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115889 · Cited by 28
Central Nervous System Targeted Protein Degraders
Thomas, B. A. I., Lewis, H. L., Jones, D. H., & Ward, S. E. (2023) · Biomolecules · doi:10.3390/biom13081164 · Cited by 30
“Necessary Steps for Targeted Protein Degradation A specific set of events must take place correctly in order to mimic or harness this process, the failure of any one of which will prevent the targeted degradation of the targeted protein (Figur 2) [5]:”
Background
The new direction of drug development: Degradation of undruggable targets through targeting chimera technology
Liang, X., Ren, H., Han, F., Liang, R., Zhao, J., & Liu, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21992 · Cited by 31
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs
Zhang, D., Ma, B., Dragovich, P. S., Ma, L., Chen, S., Chen, E. C., Ye, X., Liu, J., Pizzano, J., Bortolon, E., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00505-y · Cited by 34
“Thesepropertiesplacebi-functionalPROTACsbeyondtheLipinski ’ s rule-of-5 (bRo5) space 5 – 8 .”
Influential
Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics
Feng, Y., Hu, X., & Wang, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00638-1 · Cited by 30
“Therefore, this may result in unforeseen drug toxicity risks [188].”
Background
Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy
Lu, X., Jin, J., Wu, Y., Lin, J., Zhang, X., Lu, S., Zhang, J., Zhang, C., Ren, M., Chen, H., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.09.022 · Cited by 27
“Subse-quently, VHL ubiquitinates the target protein, and ubiquitin tags are recognized by the proteasome, leading to protein degradation [22].”
Background
Discovery and Characterization of RP03707: A Highly Potent and Selective KRAS G12D PROTAC
Ji, X. L., Li, H., Wu, G., Zhang, Q., He, X., Wu, Y., Zong, B., Xu, X., Liang, C., Wang, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00428 · Cited by 28
Emerging modes-of-action in drug discovery
Valeur, E., Narjes, F., Ottmann, C., & Plowright, A. T. (2019) · MedChemComm · doi:10.1039/c9md00263d · Cited by 29
Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery
Zeng, S., Zhang, H., Shen, Z., & Huang, W. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.639176 · Cited by 26
“…(Burslem et al., 2018), the PROTACs have no capacity for spatiotemporal control, which would dramatically reduce the incidence of offtarget effects (Churcher, 2018), given that most pharmacological protein targets are widely expressed in both healthy and diseased tissues or are overexpressed in…”
Background
Selective degradation-inducing probes for studying cereblon (CRBN) biology
Powell, C. E., Du, G., Bushman, J. W., He, Z., Zhang, T., Fischer, E. S., & Gray, N. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00382d · Cited by 29
Reversible Assembly of Proteolysis Targeting Chimeras
Gui, W., Giardina, S. F., Balzarini, M., Barany, F., & Kodadek, T. J. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00199 · Cited by 27
Optochemical Control of Protein Degradation
Wu, P., & Manna, D. (2020) · ChemBioChem · doi:10.1002/cbic.202000113 · Cited by 27
Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs
Muddassir, M., Soni, K. V., Sangani, C. B., AlArifi, A. S., Afzal, M. F., Abduh, N. A. Y., Duan, Y., & Bhadja, P. (2020) · RSC Advances · doi:10.1039/d0ra07971e · Cited by 27
Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective
Bao, S.-M., Hu, Q., Yang, W.-T., Wang, Y., Tong, Y.-P., & Bao, W.-D. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190313161009 · Cited by 26
Translating PROTAC chemical series optimization into functional outcomes underlying BRD7 and BRD9 protein degradation
Riching, K. M., Vasta, J. D., Hughes, S. J., Zoppi, V., Maniaci, C., Testa, A., Urh, M., Ciulli, A., & Daniels, D. L. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100009 · Cited by 26
ELIOT : A platform to navigate the E3 pocketome and aid the design of new PROTACs
Palomba, T., Baroni, M., Cross, S., Cruciani, G., & Siragusa, L. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14123 · Cited by 26
“PROTACs then form a ternary complex with both the substrate protein and the ubiquitin ligase (Churcher, 2018; Gu et al., 2018; Konstantinidou et al., 2019; Schapira & Crews, 2019; Scheepstra et al., 2019; Steinebach et al., 2019; Wang et al., 2019).”
Background
Anticancer strategies by upregulating p53 through inhibition of its ubiquitination by MDM2
Anifowose, A., Agbowuro, A. A., Yang, X., & Wang, B. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02574-9 · Cited by 26
“The PROTAC approach has been successfully used to develop potent degraders for various proteins (Churcher 2017; Crews 2018; Neklesa et al. 2017; Paiva and Crews 2019; Wang and Zhou 2018).”
Method
Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs
Qin, Q., Wang, R., Fu, Q., Zhang, G., Wu, T., Liu, N., Lv, R., Yin, W., Sun, Y., Sun, Y., et al. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2100886 · Cited by 24
Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
Arthur, R., Valle‐Argos, B., Steele, A. J., & Packham, G. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00009 · Cited by 24
“Due to their multi-domain nature, PROTACs are relatively large and development of agents with physiochemical properties suitable for clinical administration is likely to be challenging [10].”
Background
Enzyme-Activated Sugar-Coated Bifunctional Degraders
Zhu, Q., Fischer, G., Cheng, S. V., Payne, N. C., Peter, D., Mody, A. C., Arce-Solano, S., Shen, D., Lin, Z., Mazitschek, R., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c09843 · Cited by 22
Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system
Ma, K., Han, X.-X., Han, X., & Zhou, S. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.308075 · Cited by 24
“10|October 2021 of the target protein does not require a molar amount of the drug, it is possible to generate a highly active drug (Churcher, 2018; Crews, 2018).”
Background
Next-generation Bruton’s Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives
Das, D., Wang, J., & Hong, J. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220801101706 · Cited by 23
Recent Advances in Optically Controlled PROTAC
Ouyang, M., Feng, Y. N., Chen, H., Liu, Y., Tan, C., & Tan, Y. C. (2023) · Bioengineering · doi:10.3390/bioengineering10121368 · Cited by 25
Small Molecule Inhibitors Targeting the “Undruggable” Survivin: The Past, Present, and Future from a Medicinal Chemist’s Perspective
Cui, Q., Huang, C., Liu, J., & Zhang, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01130 · Cited by 23
Bifunctional Molecules beyond PROTACs
Conway, S. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00293 · Cited by 23
Structural and molecular bases to IRE1 activity modulation
Langlais, T., Pelizzari‐Raymundo, D., Mahdizadeh, S. J., Gouault, N., Carreaux, F., Chevet, É., Eriksson, L. A., & Guillory, X. (2021) · Biochemical Journal · doi:10.1042/bcj20200919 · Cited by 23
Nanoliposomal Bcl-xL proteolysis-targeting chimera enhances anti-cancer effects on cervical and breast cancer without on-target toxicities
Zhang, J., Zhang, B., Pu, C., Cui, J., Huang, K., Wang, H., & Zhao, Y. (2023) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-023-00649-w · Cited by 22
“Although at least 15 PROTACs have been approved in the clinic by the end of 2021 [12], there are still considerable challenges that PROTACs face.”
BackgroundInfluential
Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy
Groppe, J. C. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1660641 · Cited by 22
Degradation of intracellular TGF-β1 by PROTACs efficiently reverses M2 macrophage induced malignant pathological events
Feng, Y., Su, H., Li, Y., Luo, C., Xu, H., Wang, Y., Sun, H., Wan, G., Zhou, B., & Bu, X. (2020) · Chemical Communications · doi:10.1039/c9cc08391j · Cited by 22
Targeted Degradation of Bromodomain-Containing Protein 4 Enabled by Reactive Oxygen Species–Activatable NanoPROTACs as an Efficient Strategy to Reverse Liver Fibrosis in Chronic Liver Injury
Bi, T., Liang, P., Zhao, Q., Wu, J., Zhou, Y., Xu, Y., Fan, X., Yang, G., Sun, Q., Ren, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02658 · Cited by 21
N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan
Li, L., Wu, J., Cao, W., Zhang, W., Wu, Q., Li, Y., Yang, Y., Shan, Z., Zheng, Z., Ge, X., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02219-6 · Cited by 23
“6 Furthermore, similar techniques, such as Lysosome-targeting chimeras (LYTACs) and antibody-based PROTACs (AbTACs), 7 springs up recently for targeting out membrane proteins.”
Exploiting E3 ligases for lung cancer therapy: The promise of DCAF-PROTACs
Hussain, M. S., Eltaib, L., Rana, A. J., Maqbool, M., Ashique, S., Alanazi, M. N., Khan, Y., & Agrawal, M. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156001 · Cited by 24
Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells
Mahan, S. D., Riching, K. M., Urh, M., & Daniels, D. L. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_8 · Cited by 20
Hearing loss drug discovery and medicinal chemistry: Current status, challenges, and opportunities
Cousins, R. P. C. (2022) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2022.05.001 · Cited by 21
ASDs of PROTACs: Spray-dried solid dispersions as enabling formulations
Hofmann, N., Harms, M., & Mäder, K. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123725 · Cited by 21
Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs)
Tomaselli, D., Mautone, N., Mai, A., & Rotili, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112750 · Cited by 21
High‐Throughput Miniaturized Synthesis of PROTAC‐Like Molecules
Tian, Y., Seifermann, M., Bauer, L., Luchena, C., Wiedmann, J. J., Schmidt, S., Geisel, A., Afonin, S., Höpfner, J., Brehm, M., et al. (2024) · Small · doi:10.1002/smll.202307215 · Cited by 20
Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms
Faryal, B., Abideen, Z. U., Irfan, M., Ahmed, H., Jalilov, F. S., Abduraximova, L., & Ashraf, G. A. (2026) · Biomolecules · doi:10.3390/biom16020325 · Cited by 24
Design, synthesis, and biological evaluation of small molecule PROTACs for potential anticancer effects
Da, Y., Liu, S., Lin, P., Wang, F., Yan, R., Shu, Y., & Lin, J. (2019) · Medicinal Chemistry Research · doi:10.1007/s00044-019-02485-4 · Cited by 20
“In comparison, small molecules can access a wide range of organs and sites of action and be produced with relatively low cost of goods via a well understood development path (Churcher 2018).”
Emerging Target-Directed Approaches for the Treatment and Diagnosis of Microbial Infections
Almeida, M. C., da Costa, P. M., Sousa, E., & Resende, D. I. S. P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01212 · Cited by 20
Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
Rekha, T. N., & Shin, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065190 · Cited by 21
Androgen Receptor-Directed Molecular Conjugates for Targeting Prostate Cancer
Beretta, G. L., & Zaffaroni, N. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00369 · Cited by 21
“By interacting with AR, these chimeras direct the ligase activity on the exposed lysines of the receptor and favor ubiquitination/polyubiquitination and in turn its proteasome-mediated degradation (Churcher, 2018).”
Background
Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology
Cecchini, C., Tardy, S., Ceserani, V., Theurillat, J.-P. P., & Scapozza, L. (2020) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2020.274 · Cited by 20
Targeted delivery of a PROTAC induced PDEδ degrader by a biomimetic drug delivery system for enhanced cytotoxicity against pancreatic cancer cells.
Fan, R., He, S., Wang, Y., Qiao, J., Liu, H., Galstyan, L., Ghazaryan, A., Cai, H., Feng, S., Ni, P., et al. (2022) · PubMed Central · Cited by 20
Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation
Gross, P. H., Sheets, K. J., Warren, N. A., Ghosh, S., Varghese, R. E., Wass, K. E., & Kadimisetty, K. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.08.048 · Cited by 19
PROTAC Nanoplatform with Targeted Degradation of NAD(P)H:Quinone Oxidoreductase 1 to Enhance Reactive Oxygen Species-Mediated Apoptosis
Zhang, H., Xu, X., Yan, D., Ren, C., Zhang, J., Gu, M., Wang, Y., Wu, P., Li, Z., Kong, L., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c20312 · Cited by 20
Targeted protein modification as a paradigm shift in drug discovery
Amirian, R., Azadi Badrbani, M., Izadi, Z., Samadian, H., Bahrami, G., Sarvari, S., Abdolmaleki, S., Nabavi, S. M., Derakhshankhah, H., & Jaymand, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115765 · Cited by 18
Targeted Degradation of PD‐L1 and Activation of the STING Pathway by Carbon‐Dot‐Based PROTACs for Cancer Immunotherapy
Su, W., Tan, M., Wang, Z., Zhang, J., Huang, W., Song, H., Wang, X., Ran, H., Gao, Y., Nie, G., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202218128 · Cited by 18
Design and Evaluation of a Low Hydrogen Bond Donor Count Fragment Screening Set to Aid Hit Generation of PROTACs Intended for Oral Delivery
Whitehurst, B. C., Bauer, M. R., Edfeldt, F., Gunnarsson, A., Margreitter, C., Rawlins, P. B., & Storer, R. I. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00493 · Cited by 18
Towards the Targeted Protein Degradation of PRMT1
Martin, P. L., Pérez-Areales, F. J., Rao, S. V., Walsh, S. J., Carroll, J. S., & Spring, D. R. (2024) · ChemMedChem · doi:10.1002/cmdc.202400269 · Cited by 18
Progress in RAS‐targeted therapeutic strategies: From small molecule inhibitors to proteolysis targeting chimeras
Lu, X., Jin, J., Wu, Y., Liu, X., Liang, X., Lin, J., Sun, Q., Qin, J., Zhang, W., & Luan, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21993 · Cited by 17
“61 Owing to the unique catalytic mode of PROTACs, a low concentration of PROTACs is sufficient to trigger rapid degradation of pathogenic proteins.”
BackgroundInfluential
BET proteins: Investigating BRDT as a potential target for male contraception
Wisniewski, A. J., & Georg, G. I. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.126958 · Cited by 22
Photoactive Bifunctional Degraders: Precision Tools To Regulate Protein Stability
Kounde, C. S., & Tate, E. W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01542 · Cited by 17
A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination
Vieux, E. F., Agafonov, R. V., Emerson, L., Isasa, M., Deibler, R. W., Simard, J. R., Cocozziello, D., Ladd, B., Lee, L., Li, H., et al. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211000673 · Cited by 17
“PROTAC” modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro
Li, Y., Hwang, N., Snedeker, A., Lemon, S. M., Noe, D., Sun, L., Clement, J. A., Zhou, T., Tang, L., Block, T. M., et al. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129680 · Cited by 16
Treatment of Prostate Cancers and Kennedy’s Disease by PROTAC-Androgen Receptor Degradation
Kargbo, R. B. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00115 · Cited by 16
Design, Synthesis, and In Vitro and In Vivo Evaluation of Cereblon Binding Bruton’s Tyrosine Kinase (BTK) Degrader CD79b Targeted Antibody–Drug Conjugates
Zhang, A., Seiss, K., Laborde, L., Palacio-Ramirez, S., Guthy, D. A., Lanter, M., Lorber, J., Vulpetti, A., Arista, L., Zoller, T., et al. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00535 · Cited by 14
Targeted Protein Degradation as a Promising Tool for Epigenetic Upregulation of Fetal Hemoglobin
Verheul, T. C. J., Trinh, V. T., Vázquez, O., & Philipsen, S. (2020) · ChemMedChem · doi:10.1002/cmdc.202000574 · Cited by 14
Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease
Zhou, Q., Wang, W., & Deng, C. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04838-0 · Cited by 18
“Although PROTACs have relatively high molecular weights, they can sustain adequate intracellular levels via recycling, which allows them to effectively trigger protein degradation through catalytic processes [95].”
PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance
Giardina, S. F., Valdambrini, E., Warren, J. D., & Barany, F. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210203110857 · Cited by 14
Precise Control of Self‐assembly in vivo Based on Polymer‐Peptide Conjugates†
Xu, Y., Wang, H., & Qiao, Z. (2022) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202200459 · Cited by 14
Design, synthesis, and biological evaluation of Wee1 kinase degraders
Zhu, S., Liu, J., Xiao, D., Wang, P., Ma, J., Hu, X., Fu, J., Zhou, Y., Li, J. X., & Lu, W. P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114786 · Cited by 15
Selective degradation of cellular BRD3 and BRD4-L promoted by PROTAC molecules in six cancer cell lines
Yan, Z., Lyu, X., Lin, D., Wu, G., Gong, Y., Ren, X., Xiao, J., Lou, J., Huang, H., Chen, Y., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115381 · Cited by 14
An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16
Ma, L., Li, G. L., Yang, T., Zhang, L., Wang, X., Xu, X., & Ni, H. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04483-7 · Cited by 15
Development of Dual-Receptor Lysosome-Targeting Chimeras for Protein Degradation
Wang, K., Wang, K., Wang, C., Yang, H., Zhou, G., Ji, P., Sun, X., Gong, C., Fan, X., Hu, K., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c13695 · Cited by 13
Integrating PROTAC-based targeted protein degradation with nanodelivery systems to overcome cancer therapeutic resistance
Gou, X., He, S., Wang, B., Zhang, L., Cheng, Y., & Gao, X. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115755 · Cited by 13
An Update on Clinically Advanced PROTAC Degraders and Their Synthesis
Acharyya, R. K., Kothapalli, Y., Yarlagadda, S., De, C. K., Allu, S. R., Roy, J., & Rej, R. K. (2025) · Molecules · doi:10.3390/molecules31010033 · Cited by 13
Targeted β‐catenin ubiquitination and degradation by multifunctional stapled peptides
Wang, X., Dong, L., Cheng, J., Verdine, G. L., Lin, A., & Chu, Q. (2021) · Journal of Peptide Science · doi:10.1002/psc.3389 · Cited by 13
Small-Molecule Degraders of Cyclin-Dependent Kinase Protein: A Review
Yu, B., Du, Z., Zhang, Y., Li, Z., & Bian, J. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0154 · Cited by 14
Targeted protein degradation might present a novel therapeutic approach in the fight against African trypanosomiasis
Danazumi, A. U., Ishmam, I. T., Idris, S., Izert, M. A., Balogun, E. O., & Górna, M. W. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106451 · Cited by 14
“3A), facilitating the ubiquitination of the target protein (Churcher, 2018).”
Background
Hypoxia-selective allosteric destabilization of activin receptor-like kinases: A potential therapeutic avenue for prophylaxis of heterotopic ossification
Lu, G., Tandang‐Silvas, M. R., Dawson, A., Dawson, T. J., & Groppe, J. C. (2018) · Bone · doi:10.1016/j.bone.2018.03.027 · Cited by 14
“Similar to HyT, a bifunctional molecule is synthesized, however in place of a chaperone-baiting hydrophobic moiety, an E3 ligase-baiting group is fused to a target-specific ligand, such as a competitive inhibitor [125-137].”
Construction of PROTAC-Mediated Ternary Complex Structure Distribution Profiles Using Extensive Conformational Search
Kudo, G., Hirao, T., Harada, R., Shigeta, Y., Hirokawa, T., & Yoshino, R. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00102 · Cited by 18
TrypPROTACs Unlocking New Therapeutic Strategies for Chagas Disease
Gini, A. L. R., da Cunha, P. S. T., João, E. E., Chin, C. M., dos Santos, J. L., Serra, E. C., & Scarim, C. B. (2025) · Pharmaceuticals · doi:10.3390/ph18060919 · Cited by 12
Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future
Yao, J., Tao, Y., Hu, Z., Li, J., Xue, Z., Zhang, Y., & Lei, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1225951 · Cited by 13
Medicines discovery for auditory disorders: Challenges for industry
Cousins, R. P. C. (2019) · The Journal of the Acoustical Society of America · doi:10.1121/1.5132706 · Cited by 12
Native Mass Spectrometry: Insights and Opportunities for Targeted Protein Degradation
Sternicki, L. M., & Poulsen, S. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c03853 · Cited by 12
Potential acridinedione derivatives for the development of a heterobifunctional PROTAC for targeted degradation of PCSK9 protein
Bhardwaj, V. K., & Purohit, R. (2024) · Applied Materials Today · doi:10.1016/j.apmt.2024.102186 · Cited by 12
Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors
Funk, A. L., Katerji, M., Afifi, M. M., Nyswaner, K. M., Woodroofe, C. C., Edwards, Z. C., Lindberg, E., Bergman, K. L., Gough, N. R., Rubin, M. R., et al. (2025) · Science Signaling · doi:10.1126/scisignal.ado2857 · Cited by 11
A comprehensive primer and review of PROTACs and their In Silico design
Zattoni, J., Vottero, P., Carena, G., Uliveto, C., Pozzati, G., Morabito, B., Gitari, E., Tuszyński, J. A., & Aminpour, M. (2025) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2025.108687 · Cited by 14
Bifunctional robots inducing targeted protein degradation
Sobhia, M. E., Kumar, H., & Kumari, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115384 · Cited by 11
A First-Class Degrader Candidate Targeting Both KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination
Miyamoto‐Sato, E., Imanishi, S., Huang, L., Itakura, S., Iwasaki, Y., & Ishizaka, M. (2023) · Molecules · doi:10.3390/molecules28145600 · Cited by 13
PROTAC for agriculture: learning from human medicine to generate new biotechnological weed control solutions
León, R. G., & Bassham, D. C. (2023) · Pest Management Science · doi:10.1002/ps.7741 · Cited by 10

Authors: Churcher, I.
Affiliations: BenevolentBio, 40 Churchway, London NW1 1LW, U.K.
Corresponding author: Churcher, Ian
ORCID: Churcher, Ian
Venue: Journal of Medicinal Chemistry
Publisher: American Chemical Society (ACS)
Published: 2017-12-19
Volume: 61
Issue: 2
Pages: 444-452
ISSN: 0022-2623 (ISSN-L)
1520-4804
DOI: 10.1021/acs.jmedchem.7b01272
OpenAlex: W2769590617
Cited by: 491
References: 67
Citations by year: 2026: 45 · 2025: 61 · 2024: 49 · 2023: 56 · 2022: 53 · 2021: 54 · 2020: 84 · 2019: 64 · 2018: 22 · 2017: 1
FWCI: 4.43
Type: journal article
Language: en
Open access: closed
Locations: Journal of Medicinal Chemistry (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords: targeted protein degradation, PROTACs, bifunctional small molecules, protein degradation, drug discovery
MeSH terms: Humans, Peptides, Recombinant Proteins, Drug Design, Ubiquitin-Protein Ligases, Small Molecule Libraries, Ubiquitination, Drug Discovery, Molecular Targeted Therapy, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks